OncoMatch/Clinical Trials/NCT05838716
Vitamin D for Prostate Endocrine Therapy
Is NCT05838716 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for stage i prostate cancer ajcc v8.
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage I, II, III, IVA
Demographics
Prior therapy
Must have received: LHRH agonist — starting or within past 6 months
Be starting ADT or have received their first ADT treatment in the past 6 months, with a total of at least 6 planned months of treatment (both luteinizing hormone-releasing hormone [LHRH] antagonists and LHRH agonists are permitted)
Must have received: LHRH antagonist — starting or within past 6 months
Be starting ADT or have received their first ADT treatment in the past 6 months, with a total of at least 6 planned months of treatment (both luteinizing hormone-releasing hormone [LHRH] antagonists and LHRH agonists are permitted)
Cannot have received: pharmacologic bone-modifying agent (oral bisphosphonates, intravenous bisphosphonates, denosumab, teriparatide)
Have long term (greater than 3 months) use of any pharmacologic bone-modifying agent including but not limited to oral or intravenous (IV) bisphosphonates, denosumab, or teriparatide prior to enrollment
Lab requirements
Kidney function
normal GFR (glomerular filtration rate > 30ml); exclusion: stage IV chronic kidney disease
Have a normal GFR (glomerular filtration rate > 30ml); Have a diagnosis of stage IV chronic kidney disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Helen F Graham Cancer Center · Newark, Delaware
- Medical Oncology Hematology Consultants PA · Newark, Delaware
- Carle at The Riverfront · Danville, Illinois
- Cancer Care Specialists of Illinois - Decatur · Decatur, Illinois
- Carle Physician Group-Effingham · Effingham, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05838716 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pharmacologic bone-modifying agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III or IVA is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages